Aspirin for Stable Angina Pectoris
For stable angina pectoris (chronic coronary syndrome), aspirin 75-100 mg daily is the recommended single antiplatelet agent, not clopidogrel. 1
Primary Recommendation
Aspirin remains the first-line antiplatelet monotherapy for patients with stable coronary artery disease based on current guidelines 1. The 2024 ESC Guidelines for Chronic Coronary Syndromes explicitly recommend aspirin 75-100 mg daily as the standard antiplatelet therapy for secondary prevention in stable patients.
When to Consider Clopidogrel Instead
Clopidogrel 75 mg daily should be used only in specific circumstances:
- Aspirin intolerance or hypersensitivity - This is the primary indication for switching to clopidogrel monotherapy 2, 3
- Major gastrointestinal intolerance to aspirin that cannot be managed with proton pump inhibitors 2
- Aspirin allergy with documented hypersensitivity reactions 4
Evidence Base
The CAPRIE trial demonstrated that clopidogrel alone was slightly more effective than aspirin alone in reducing combined risk of ischemic stroke, MI, or vascular death in patients with atherosclerotic vascular disease 5. However, this marginal benefit (relative risk reduction of approximately 8.7%) has not changed guideline recommendations to prefer clopidogrel over aspirin as first-line therapy in stable disease.
Important distinction: The evidence supporting clopidogrel superiority comes primarily from:
- Post-ACS populations where dual antiplatelet therapy transitions to monotherapy 6, 7
- Patients with prior bleeding on aspirin
- Selected high-risk populations
These contexts differ fundamentally from treatment-naive stable angina patients.
Practical Algorithm
- Start with aspirin 75-100 mg daily for all stable angina patients
- Switch to clopidogrel 75 mg daily only if:
- Documented aspirin allergy/hypersensitivity
- Severe GI intolerance despite PPI therapy
- Aspirin-related bleeding that cannot be managed
- Do not routinely use clopidogrel as first-line in stable disease without these contraindications
Critical Caveats
- This recommendation applies to stable angina only - not acute coronary syndromes where dual antiplatelet therapy (aspirin + P2Y12 inhibitor) is mandatory 8, 2
- Post-PCI patients require different management with mandatory DAPT for defined durations 9
- Cost considerations favor aspirin, which is significantly less expensive than clopidogrel
- Bleeding risk is similar between aspirin and clopidogrel monotherapy in stable patients, though CAPRIE showed slightly less GI bleeding with clopidogrel 5
The guideline consensus remains clear: aspirin is the default antiplatelet agent for stable coronary disease, with clopidogrel reserved as an alternative when aspirin cannot be tolerated 1.